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Summary DT-diaphorase is a two-electron-reducing enzyme that is an important activator of bioreductive anti-tumour agents, such as
mitomycin C (MMC) and E09, and is inducible by many compounds, including 1,2-dithiole-3-thiones (D3Ts). We showed previously that D3T
selectively increased DT-diaphorase activity in mouse lymphoma cells compared with normal mouse marrow cells, and also increased MMC or
E09 cytotoxic activity in the lymphoma cells with only minor effects in the marrow cells. In this study, we found that D3Tsignificantly increased
DT-diaphorase activity in 28 of 38 human tumourcell lines representing ten tissue types with no obvious relationships between the tumourtype,
orthe base level of DT-diaphorase activity, and the ability of D3T to increase the enzyme activity. Induction of DT-diaphorase activity in human
tumour cell lines by 12 D3T analogues varied markedly with the D3T structure. D3T also increased DT-diaphorase activity in normal human
bone marrow and kidney cells but the increases were small in these cells. In addition, D3T increased the level of enzyme activity in normal
human lung cells. Pretreatment of human tumourcells with D3Tanalogues significantly increased thecytotoxic activity of MMC or E09 in these
cells, and the level of enhancement of anti-tumour activity paralleled the level of DT-diaphorase induction. In contrast, D3T did not effect the
toxicity of E09 in normal kidney cells. These results demonstrate that D3T analogues can increase DT-diaphorase activity in a wide variety of
human tumour cells and that this effect can enhance the anti-tumour activity of the bioreductive agents MMC and E09.
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NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase)
(EC 1.6.99.2) is a flavoprotein that catalyses obligatory two-elec-
tron reduction ofquinones, quinone imines, azo dyes and nitrogen
oxides (Riley and Workman, 1992). The enzyme is found in all
eukaryotes and is present at varying levels in most tissues (Benson
et al, 1980; Belinsky and Jaiswal, 1993). DT-diaphorase is located
mainly in the cytosol, but5-10% is membrane bound in mitochon-
dria, microsomes and Golgi apparatus (Riley and Workman,
1992). The enzyme has two identical subunits with individual
molecular weights of 32 kDa and requires NADH or NADPH as
an electron donor for enzymatic activity (Riley and Workman,
1992). Several DT-diaphorases have been identified in humans
(Jaiswal et al, 1990; Jaiswal, 1991), but the NQO, gene has been
most extensively studied and appears to be most important for
activation of bioreductive anti-tumour agents (Jaiswal, 1991;
Riley and Workman, 1992; Belinsky and Jaiswal, 1993). Enzyme
levels have been shown to be relatively high in mouse and/or
human stomach, bladder, intestine, colon and kidney, but are
usually low in liver, lung and haematopoietic cells (Benson et al,
1980; Schlager and Powis, 1990; Smitskamp-Wilms et al, 1995).
DT-diaphorase activity is higher in some tumour cells than in the
corresponding normal cells, with elevated levels of enzyme
activity having been observed in human liver, colon, breast and
lung tumour cells (Schlager and Powis, 1990; Malkinson et al,
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1992; Belinsky and Jaiswal, 1993; Smitskamp-Wilms et al, 1995).
DT-diaphorase is a phase II detoxifying enzyme that is involved
in metabolizing xenobiotics and carcinogens, thereby protecting
the cell from their toxic and mutagenic effects (Beyer et al, 1988;
Riley and Workman, 1992). There has been considerable interest
in the role of this enzyme, and other phase II enzymes, such as
glutathione S-transferases (GST), epoxide hydrolase and UDP-
glucuronosyltransferases, in early cellular defence mechanisms
against tumorigenesis (Beyer et al, 1988; Prestera et al, 1993). DT-
diaphorase is induced in many tissues by a wide variety of
structurally dissimilar chemicals, including 1,2-dithiole-3-thiones
(D3Ts), quinones, diphenols, phenylenediamines, Michael reac-
tion acceptors, isothiocyanates and heavy metals (Prestera et al,
1993). Thus, studies have investigated the use of inducers of DT-
diaphorase and other phase II detoxifying enzymes in cancer
prevention (Kelloff et al, 1990; Kensler and Helzlsouer, 1995).
Oltipraz, a D3T analogue used for treatment of schistosomiasis
(Bueding et al, 1982), is an inducer of phase II detoxifying
enzymes (Kensler et al, 1992; Egner et al, 1994; Kensler and
Helzlsouer, 1995) and inhibits development oftumours in animals
(Kelloff et al, 1990; Kensler et al, 1992; Kensler and Helzlsouer,
1995). This agent has low toxicity in animals and is in phase I and
II clinical trials as a chemoprotective agent in humans (Kensler et
al, 1992; Maxuitenko et al, 1996; O'Dwyer et al, 1996). Because
oftheir ability to induce phase II enzymes and their relatively low
toxicity, otherD3T analogues are also being investigated as cancer
preventative agents (Egner et al, 1994).
DT-diaphorase has been shown to be an important activating
enzyme for bioreductive anti-tumour agents, such as mitomycin C
(MMC) (Begleiter et al, 1989; Ross et al, 1993; Mikami et al,
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1996), 3-hydroxymethyl-5-aziridinyl-l-methyl-2(1H-indole-4,7-
dione)prop-,B-en-a-ol (EO9) (Plumb et al, 1994), diaziquone
(Siegel et al, 1990), streptonigrin (Beall et al, 1996) and others
(Workman and Stratford, 1993) in many systems. Bioreductive
agents require intracellular activation by either two-electron-
reducing enzymes, such as DT-diaphorase (Ross et al, 1993;
Plumb et al, 1994) and xanthine dehydrogenase (EC 1.1.1.204)
(Gustafson and Pritsos, 1992) or by one-electron-reducing
enzymes, such as NADPH:cytochrome P450 reductase (EC
1.6.2.4) (Pan et al, 1984) and NADH:cytochrome b5 reductase (EC
1.6.2.2) (Hodnick and Sartorelli, 1993). In general, cell lines
(Begleiter et al, 1989; Malkinson et al, 1992; Ross et al, 1993;
Mikami et al, 1996) or tumour specimens (Nishiyama et al, 1993)
with higher levels of DT-diaphorase are more sensitive to MMC.
A significant correlation was found between the level of DT-
diaphorase activity and sensitivity to MMC and E09 in the human
tumour cell lines of the National Cancer Institute Tumour Cell
Line Panel (Fitzsimmons et al, 1996). E09 activity appears to be
particularly sensitive to the level of DT-diaphorase under
oxygenated conditions (Plumb et al, 1994). Increasing DT-
diaphorase activity in gastric carcinoma (Mikami et al, 1996) or
Chinese hamster ovary cells (Belcourt et al, 1996), by transfection
of the NQO, gene, increased the sensitivity of the cells to MMC.
In contrast, transfection of the NQO, gene into NIH 3T3 mouse
fibroblasts did not increase MMC activity in these cells (Powis et
al, 1995). In addition, DT-diaphorase did not appear to play a
major role in activation of MMC in some cell lines in vivo
(Nishiyama et al, 1993) or under hypoxia (Begleiter et al, 1992;
Belcourt et al, 1996). Furthermore, DT-diaphorase did not effect
the toxicity of the benzotriazine di-N-oxide, tirapazamine
(Patterson et al, 1994) and protected cells from the toxicity of the
quinone agents, menadione (Atallah et al, 1988), hydrolysed
benzoquinone mustard, benzoquinone mustard and benzoquinone
dimustard (Begleiter and Leith, 1990).
A study by Shao et al (1995) found that high levels of dietary
fish oil lowered the growth rate of MX-1, human mammary carci-
noma, xenografts in athymic mice and increased DT-diaphorase
activity in the tumour. The high levels offish oil also increased the
response of the tumour to MMC. We have previously shown
(Begleiter et al, 1996) that D3T selectively increased the level of
DT-diaphorase activity in L5178Y murine lymphoma cells with no
effect on the activity of this enzyme in normal marrow cells from
DBA/2 mice. Combination treatment ofL5178Y tumour cells with
D3T and MMC produced a twofold increase in cytotoxic activity
compared with MMC alone. Similar treatment with D3T and E09
produced a sevenfold increase in anti-tumour activity compared
with E09 alone. By comparison, D3T did not enhance the activity
ofMMC in normal mouse marrow cells and produced only a small
increase in E09 cytotoxicity in these cells. The DT-diaphorase
inhibitor dicoumarol inhibited the effect of D3T on the anti-
tumouractivity ofthe bioreductive agents, supporting the proposal
that the enhanced anti-cancer activity was due to the elevated level
ofenzyme activity.
These findings suggest that inducers of DT-diaphorase, such as
D3T analogues, may be useful to enhance the anti-tumourefficacy
of bioreductive anti-tumour agents. Although induction of DT-
diaphorase by D3T analogues has been studied previously in
rodent tissues in the context of cancer chemoprevention, in this
study we investigated the ability ofD3T analogues to increase the
level ofDT-diaphorase activity in human tumour and normal cells
as a way of enhancing the anti-tumour activity of bioreductive
agents. We examined induction of the enzyme in tumour cell lines
from different tissues and in cell lines having different base levels
of DT-diaphorase. It has been shown previously (Egner et al,
1994) that induction of DT-diaphorase in mouse hepatoma cells
was dependent on the chemical structure of the D3T analogue.
Thus, we also investigated the ability of D3T analogues to induce
DT-diaphorase activity in human tumour cell lines to identify
structure-activity relationships that might be useful fordeveloping
more potent and selective enzyme inducers. Finally, we evaluated
the effect of combining D3T analogues with MMC or E09 on the
cytotoxic activity of these bioreductive anti-tumour agents in
human tumour and normal cell lines.
MATERIALS AND METHODS
Materials
All media, fetal bovine serum (FBS) and insulin transferrin sele-
nium (ITS) were obtained from Gibco BRL (Grand Island, NY,
USA). All reagents for the DT-diaphorase assay, hydrocortisone,
Ficoll 400, lactalbumin hydrosylate, 3-[4,5-dimethylthiazol-2-yl]-
2,5-diphenyltetrazolium bromide (MTT) and MMC were from
Sigma (St Louis, MO, USA). E09 was kindly supplied by Dr HR
Hendriks, New Drug Development Office, European Organization
for Research and Treatment of Cancer, Amsterdam, The
Netherlands. MMC was dissolved in phosphate-buffered saline
(PBS), while E09 was dissolved either in dimethyl sulphoxide
(DMSO) or DMSO-ethanol (2:3, v:v). The final concentration of
DMSO or ethanol did not exceed 1%. The D3T analogues were
synthesized by Dr TJ Curphey. D3T analogues were prepared in
ethanol at a concentration of 2 x 10-2 M with the exceptions of
ADT, which was prepared at 1 x 10-2 M in ethanol, and Oltipraz,
which was prepared at 2 x 10-2 M in DMSO or at 5 x 10-3 M in
acetone. The final concentration of acetone did not exceed 2% and
that of DMSO or ethanol did not exceed 1% in the cell incubation
media. Appropriate media and FBS at pH 7.2 were used for all DT-
diaphorase induction studies and incubations with MMC or E09.
Cells
HL-60, promyelocytic leukaemia cells, were obtained from Dr AH
Greenberg, Manitoba Institute of Cell Biology, Winnipeg, Canada,
and were grown in RPMI 1640 medium and 10% FBS. THP-1,
monocytic leukaemia cells, were obtained from Dr D Houston,
Manitoba Institute ofCell Biology, and were grown in RPMI 1640
and 10% FBS. WIL-2, B lymphoblastoid leukaemia cells, were
purchased from American Type Culture Collection (Rockville,
MD) and were grown in RPMI 1640 and 10% FBS. SCC-25,
tongue squamous carcinoma cells, were from American Type
Culture Collection and were grown in Dulbecco's Modified Eagle
Medium (DMEM) F-12(1:1) with 0.4,ug ml-I of hydrocortisone
and 10% FBS. Detroit 562, pharynx carcinoma cells, were from
American Type Culture Collection and were grown in DMEM/F-
12(1:1) with 0.1% lactalbumin hydrosylate and 10% FBS. FaDu,
pharynx squamous carcinoma cells, were from American Type
Culture Collection and were grown in DMEM/F-12(1:1) and 10%
FBS. NCI-H596, lung adenosquamous carcinoma cells, NCI-H209,
lung small-cell carcinoma cells, NCI-H661, lung large-cell carci-
noma cells, and NCI-H520, lung squamous carcinoma cells, were
obtained from American Type Culture Collection and were grown
in RPMI 1640 and 10% FBS. NCI-H125, lung non-small-cell
adenocarcinoma cells, were obtained from Dr SS Pan, University
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Figure 1 Induction of DT-diaphorase in HL-60 cells by D3T. HL-60 cells
were incubated with various concentrations of D3T at 370C for 48 h and DT-
diaphorase activity was measured as described in Materials and methods.
The data represent the mean ± standard error of four or five determinations
ofMaryland Cancer Center, Baltimore, MD, USA, and were grown
in RPMI 1640 and 10% FBS. Colo32ODM, colon carcinoma cells,
were from American Type Culture Collection and were grown in
RPMI 1640 and 10% FBS. HCT116 and LS174T, colon carcinoma
cells, were from American Type Culture Collection and were
grown in DMEMIF-12(1:1) and 10% FBS. Colo2O5, colon adeno-
carcinoma cells, were obtained from Dr AH Greenberg and were
grown in RPMI 1640 and 10% FBS, while HT29, colon adenocar-
cinomacells, were obtained from DrJB Johnston, Manitoba Cancer
Treatment and Research Foundation, Winnipeg, Canada, and were
grown in RPMI 1640 and 10% FBS. RF-48 and RF-1, gastric
adenocarcinoma cells, were from DrJA Wright, Manitoba Institute
of Cell Biology, and were grown in alpha minimal essential
medium (MEM) and 10% FBS. AGS, gastric adenocarcinoma
cells, and Kato III, gastric carcinoma cells, were obtained from
DrJA Wright and were grown in RPMI 1640 and 10% FBS. MDA-
MB-231, breast adenocarcinoma cells, were from American Type
Culture Collection and were grown in IMDM and 10% FBS.
MDA-MB-468, breast adenocarcinoma cells, were obtained from
American Type Culture Collection and were grown in DMEM/F-
12(1:1) with 1% ITS and 10% FBS. T47D, breast ductal carcinoma
cells, were from Dr S Mai, Manitoba Institute ofCell Biology, and
were grown in RPMI 1640 with 1% ITS and 10% FBS. BT474,
breast ductal carcinoma cells, were from Dr SS Pan and were
grown in DMEM/F-12(1:1) with 1% ITS and 10% FBS. SK-Br-3,
breast adenocarcinoma cells, were obtained from American Type
Culture Collection and were grown in McCoy's medium and 10%
FBS. MDA-MB-435, breast ductal carcinoma cells, were from Dr
EA Turley, Manitoba Institute of Cell Biology, and were grown in
DMEM/F-12(1:1) and 10% FBS. HS578T, breast ductal carcinoma
cells, and ZR-75-1, breast carcinoma cells, were obtained from Dr
SS Pan and were grown in DMEM/F-12(1:1) and 10% FBS. MCF-
7, breast adenocarcinoma cells, were from Dr AH Greenberg and
were grown in RPMI 1640 and 10% FBS. OVCAR-3, ovarian
adenocarcinoma cells, were from American Type Culture
Collection and were grown in RPMI 1640 with 1% ITS and 20%
FBS. SK-OV-3, ovarian adenocarcinoma cells, were from
American Type Culture Collection and were grown in McCoy's
medium and 10% FBS. PC-3, prostate adenocarcinoma cells, and
DU145, prostate carcinoma cells, were obtained from Dr J Dodd,
University of Manitoba, Winnipeg, Canada, and were grown in
DMEM/F-12(1:1) and 10% FBS. LnCAP, prostate adenocarcinoma
cells, were fromDrJ Dodd and were grown in RPMI 1640 and 10%
FBS. SK-MEL-28, SK-MEL-2 and SK-MEL-5, malignant
melanoma cells, were obtained from American Type Culture
Collection and were grown in DMEM/F-12(1:1) and 10% FBS.
HepG2, hepatocellular carcinoma cells, were from American Type
Culture Collection and were grown in alpha MEM and 15% FBS.
Normal marrow specimens were obtained from marrow donated for
transplantation and mononuclear cells were isolated using a Ficoll-
Hypaque gradient (Johnston et al, 1994). WI-38, human embryonic
lung cells, were obtained from Dr JA Wright and were grown in
alpha MEM and 10% FBS, while 293, human embryonic kidney
150 cells, were from Dr M Mowat, Manitoba Institute of Cell Biology,
and were grown in DMEM/F-12(1:1) and 10% FBS.
Induction of DT-diaphorase
Exponentially growing cells were treated with D3T analogues at
37°C for various periods of time. Cells were washed, pelleted,
suspended in 100-200gl of0.25 M sucrose, sonicated and stored at
-80°C. DT-diaphorase activity was measured, using menadione as
the electron acceptor, by the assay of Prochaska and Santamaria
(1988), modified for use in a semi-microcuvette. Briefly, 5-100 ±g
of protein was assayed for DT-diaphorase activity by adding the
appropriate volume of sucrose sonicate to a semi-microcuvette
containing 750 g1 of the assay stock solution (Prochaska and
Santamaria, 1988). The increase in absorbance at 25°C at 610 nm
was followed for up to 10 min using a Cary I spectrophotometer.
Duplicate cuvettes were prepared for each sample, one for total
activity and one with 10gM dicoumarol. The DT-diaphorase
activity reported was the dicoumarol-inhibitable activity. DT-
diaphorase activity was expressed as nmol MIT min-' mg-'
protein. Enzyme activities as low as 1.0 nmol MTT min-' mg-'
protein could be detected with this assay procedure. Protein
concentration was measured using the Bio-Rad DC Kit (Bio-Rad,
Mississauga, Canada) with gamma globulin as standard. The
concentrations ofthe D3T analogues used in these studies produced
little or no toxicity to the cells during the incubation period.
Measurement of GST activity
GST activity was tneasured in the supernatant of cell sonicates by
a previously described spectrophotometric procedure (Habig et al,
1974) using 1-chloro-2,4-dinitrobenzene as substrate.
Measurement of NADPH:cytochrome P450 reductase
activity
NADPH-cytochrome P450 reductase activity was determined in
supematants from cell sonicates by a spectrophotometric assay
using cytochrome c as the artificial electron acceptor (Strobel and
Digman, 1978).
Measurement of NADH:cytochrome b5 reductase
activity
NADH:cytochrome b5 reductase activity was determined spec-
trophotometrically using the method of Barham et al (1996),
which measures the pHMB-inihibitable, NADH-dependent reduc-
tion ofcytochrome c.
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Table 1 Induction of DT-diaphorase in human tumour cell lines by D3T
DT-diaphorase activity
Tumour Cell line Mean ± s.e. (nmol MTT min-' mg-' protein) P
type
Control D3T induced
Leukaemia
Head and neck
Lung
Colon
Stomach
Breast
Ovary
Prostate
Skin
Liver
HL-60
THP-1
WIL-2
SCC-25
Detroit 562
FaDu
NCI-H596
NCI-H209
NCI-H661
NCI-H520
NCI-H125
CoIo32ODM
HCT116
LS174T
Colo2O5
HT29
RF-48
RF-1
AGS
Kato IlIl
MDA-MB-231
MDA-MB-468
T47D
BT474
SK-Br-3
MDA-MB-435
HS578T
ZR-75-1
MCF-7
OVCAR-3
SK-OV-3
PC-3
LnCAP
DU145
SK-MEL-28
SK-MEL-2
SK-MEL-5
HepG2
4.0 ± 0.5
26.1 ±2.3
58.8 ± 4.4
39.7 ± 7.8
167.7 ± 27.9
463.2 ± 29.9
1.0 ± 0.2
8.3 ± 0.8
112.8 ± 12.4
230.1 ± 31.3
689.5 ± 39.0
ND
89.8± 11.9
314.6 ± 39.0
671.2 ± 64.5
713.1 ± 47.4
6.9 ± 0.3
7.7 ± 0.5
138.5 ± 25.7
167.0 ± 6.7
ND
4.4 ± 2.5
27.9 ± 1.2
191.5± 10.1
213.0 ± 1.5
232.2 ± 16.2
237.9 ± 13.9
355.5 ± 43.0
939.1 ± 88.3
47.2 ± 5.9
177.8 ± 8.6
149.3 ± 5.0
166.0 ± 15.1
652.3 ± 30.0
586.7 ± 19.6
666.5 ± 30.6
2120.0 ± 51.3
1292.5 ± 162.0
31.1 ±3.4
102.8 ± 5.4
139.2 ± 8.9
66.1 ± 16.7
199.7 ± 39.3
444.1 ± 45.2
3.5 ± 0.6
40.2 ± 3.1
284.8 ± 27.3
267.0 ± 36.5
1136.0 ± 52.1
ND
205.1 ± 35.3
776.1 ± 97.5
1117.3 ± 111.5
944.6 ± 69.1
22.7± 1.0
22.7 ± 0.4
294.6 ± 31.9
289.3 ± 11.0
1.9 ± 0.5
ND
97.6 ± 4.5
430.8 ± 36.1
331.0 ± 13.7
291.7± 16.0
420.8 ± 19.0
592.5 ± 71.7
981.2 ± 96.5
129.3 ± 10.9
259.0 ± 15.9
183.0± 1.7
266.2 ± 34.5
632.0 ± 20.1
828.7 ± 38.4
796.3 ± 36.5
2710.0 ± 60.8
1356.3 ± 141.3
<0.001
<0.001
<0.001
NS
NS
NS
<0.005
<0.001
<0.001
NS
<0.001
<0.02
<0.005
<0.005
<0.02
<0.001
<0.001
<0.005
<0.001
<0.001
<0.001
<0.002
<0.02
<0.001
<0.02
NS
<0.001
<0.002
<0.005
<0.02
NS
<0.005
<0.05
<0.002
NS
ND, not detected; NS, not significant. Cells were incubated with or without 100gM D3T at 370C for 48 h. Cells were washed,
pelleted, suspended in 100-200 li of 0.25 M sucrose, sonicated and stored at-800C. DT-diaphorase activity was measured as
described in Matenals and methods using menadione as the electron acceptor. The data represent the mean ± standard error of
3-15 determinations. Statistical significance was determined using a two-tailed t-testcomparng the significance of the difference
of the mean DT-diaphorase activity in control and D3T-treated cells.
Measurement of xanthine dehydrogenase activity
Xanthine dehydrogenase activity was determined using the spec-
trophotometric method of Gustafson et al (1991). This method
follows the formation of uric acid from xanthine in the presence
and absence of NAD+ to distinguish the xanthine dehydrogenase
and xanthine oxygenase forms ofthe enzyme.
Cytotoxicity studies
HL-60, human promyelocytic leukaemia cells, or 293, human
normal kidney cells, were incubated with orwithout 50 gM D3T or
50 S M Oltipraz for 48 h and then were treated with various
concentrations ofE09 for 1 h. The surviving cell fraction for HL-
60 cells was determined by clonogenic assay (Begleiter et al,
British Journal ofCancer (1998) 77(8), 1241-1252 0CancerResearch Campaign 1998Induction ofDT-diaphorase in human tumourcelllines 1245
S
CH3S OH3
CH3S H
CH3
CH3 S-/
NH2+
CH3-
Analogue 9 Analogue 10
Figure 2 Structures of D3T analogues used in this investigation
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1989), and colonies were counted after 14 days. The surviving cell
fraction for 293 kidney cells was determined by MTT assay
(Johnston etal, 1994) after 8 days. Forstudies with dicoumarol, 50
,UM dicoumarol was added 15 min before treatment with E09.
H661 cells were incubated at 37°C for48 h with or without 50 ,UM
D3T or 50gM analogue 8 and then were incubated with various
concentrations ofE09 for 1 h. T47D cells were incubated with or
without 75 ,UM D3T for 48 h and then were treated with various
concentrations of MMC for 1 h. The surviving cell fraction was
determined by MTT assay (Johnston et al, 1994) after 7-12 days.
TheDo (concentration ofdrug required to reduce the surviving cell
fraction to 0.37) was obtained from the linearregression line ofthe
ln(surviving cell fraction) vs drug concentration curve. The Do
values for different treatments were compared using a t-test
comparing the significance of the differences of the slopes of the
linear regression lines. The concentrations ofD3T and dicoumarol
used in these studies were not toxic to the cells.
RESULTS
Induction of DT-diaphorase by D3T in human tumour
cells
When NCI-H661, lung carcinoma cells, were incubated with
100,M D3T for up to 72 h, the level of DT-diaphorase activity
increased with time but reached a maximum at 48 h. Incubation of
HL-60, promyelocytic leukaemia cells, with increasing concentra-
tions of D3T for 48 h resulted in increasing levels of DT-
diaphorase activity that reached a maximum at 100 ,UM D3T and
decreased at higher concentrations (Figure 1). Thus, for induction
studies, the human cell lines were incubated for 48 h with 100 ,UM
D3T analogue. Incubation of HL-60 cells with 100 ,UM D3T for
48 h did not increase the levels ofGST, NADPH:cytochrome P450
reductase or NADH:cytochrome b5 activity. Xanthine dehydro-
genase activity was too low to be detected in HL-60 cells after
incubation with or without 100gM D3T for48 h.
The level of DT-diaphorase activity was measured in 38 human
tumour cell lines after incubation with or without 100gM D3T for
48 h (Table 1). Tumour cell lines from ten different tumour types
were studied, including leukaemia, head and neck, lung, colon,
stomach, breast, ovary, prostate, melanoma and liver. The base
level of DT-diaphorase activity in the cells ranged from < 1.0 to
2120 nmol MTT min-' mg-' protein. Enzyme activity was signifi-
cantly increased with D3T incubation in 28 of the cell lines, with
the increase ranging from 1.2- to 8.0-fold, or from 2.5 to 590 nmol
MTT min-1 mg-' protein in absolute terms. Cells from all tumour
types appeared to be inducible with the exception ofhead and neck
and liver tumours. Four of five lung tumour cell lines showed
increased DT-diaphorase activity after incubation with D3T, and
this included both small-cell and non-small-cell lung tumours. Six
of nine breast carcinoma cell lines were inducible by D3T, with
most of the cell lines having intermediate base levels of DT-
diaphorase being induced. Oestrogen receptor status did not appear
to influence enzyme induction as three ofthe induced breastcancer
cell lines wereoestrogen receptorpositive andthree were oestrogen
receptor negative. Similarly, D3T increased DT-diaphorase activity
in two of three prostate carcinoma cell lines; one induced cell line
was androgen receptor positive, while the other was androgen
receptor negative. Four offive colon tumours and all the malignant
melanoma cell lines studied showed significantly increased levels
ofDT-diaphorase activity aftertreatment with D3T, despite the fact
that many of these cells had very high base levels of enzyme
activity. D3T also increased DT-diaphorase activity in all the
leukaemias, stomach tumours and ovarian tumours studied.
Table 2 Induction of DT-diaphorase in human tumour cell lines by D3T analogues
DT-diaphomse activity mean ± s.e. (nmol MTT min-' mg- protein)
Inducer HL-60 THP-1 NCI-H209 NCI-H661 LS174T HT29 MCF-7 HepG2
Control 4.5 ± 0.5 26.1 ± 2.3 8.3 ± 0.8 112.8 ± 12.4 314.6 + 39.0 713.1 + 47.4 939.1 ± 88.3 1292.5 ± 162.0
D3T 31.6 ± 3.6* 102.8 ± 5.4* 40.2 ± 3.1* 284.8 ± 27.3* 776.0± 97.5* 944.6 ± 69.1* 981.3 ± 96.5 1356.3 ± 141.3
Oltipraz 17.8 ± 3.3* 57.8 0.8* 10.7 ± 3.5 132.0 24.9 421.7 43.2 813.1 ±82.2 - -
ADT 7.6 ± 1.9* 22.3 + 0.6 10.4 ± 4.3 158.8 ± 25.2 524.7 ± 73.2* 718.0 + 31.6 - -
Analogue 1 7.7 ± 0.8* 45.3 + 2.8* 6.2 ± 1.7 203.2 ± 35.6* 658.4 ± 48.7* 793.3 + 72.9 904.0 ± 122.6 1174.9 ± 143.2
Analogue 2 9.3 ± 0.6* 52.1 ± 4.5* 10.0 ± 0.8 171.7 ± 39.5 573.7 ± 72.4* 766.1 + 64.9 920.7 ± 252.3 1123.2 ± 94.2
Analogue 3 6.4 ± 0.6 41.6 ± 3.2* 7.3 ± 0.5 180.1 ± 41.0* 672.8 ± 55.9* 833.0 ± 69.4 657.2 ± 153.7 1069.2 ± 144.2
Analogue 4 12.2 ± 1.0* 59.4 ± 5.0* 13.6 ± 2.4* 187.7 + 33.1* 666.5 ± 49.9* 892.2 ± 80.0 1041.5 ± 154.3 1175.3 + 156.6
Analogue 5 7.5 ± 1.4* 53.9 ± 5.6* 7.7 ± 1.7 168.0 + 26.8* 482.7 ± 29.6* 907.7 ± 78.5* 672.3 ± 219.1 1011.4 + 76.2
Analogue 6 9.9 + 1.1* 48.7 ± 4.4* 6.9 ± 2.3 190.0 ± 35.3* 652.5 ± 90.2* 682.0 ± 91.4 638.9 ± 130.0 1272.2± 102.1
Analogue 7 38.4 ± 5.8* 124.2 ± 11.6* 26.4 ± 2.7* 309.9 ± 58.9* 596.9 ± 40.9* 752.7 ± 98.2 805.1 ± 120:4 1048.4± 143.7
Analogue 8 7.4 ± 0.8* 76.1 ± 2.8* 8.0 ± 3.2 205.9 ± 34.2* 640.5 ± 67.0* 1110.5 ± 87.4* 604.4 ± 217.5 1031.4± 107.1
Analogue 9 24.2 ± 2.5* 38.4 ± 6.3* 24.3 ± 3.0* 289.9 ± 37.9* 678.8 ± 79.1* 842.4 ± 134.0 691.7 ± 225.8 1232.6 ± 95.7
Analogue 10 3.9 ± 0.5 44.5 ± 3.7* 8.1 ± 1.0 129.2 ± 18.3 336.4 ± 46.6 672.9 ± 58.0 - 993.7 ± 116.9
*P < 0.05 compared with control. Cells were incubated with or without 100gM of each D3T analogue at 370C for 48 h. Cells were washed, pelleted, suspended
in 200-300,l of 0.25 M sucrose, sonicated and DT-diaphorase activity was measured as described in Materials and methods using menadione as the electron
acceptor. The data represent the mean ± standard error of 3-11 determinations. Statistical significance was determined using a two-tailed t-test comparing the
significance of the difference of the mean DT-diaphorase activity in control and D3T analogue-treated cells.
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Figure 3 Effect of Oltipraz or D3T on cytotoxic activity of E09 and DT-
diaphorase activity in HL-60, human promyelocytic leukaemia cells. Cells
were incubated at 370C with or without 50 gM Oltipraz or 50 gM D3T for 48 h.
Cells were then treated with various concentrations of E09 for 1 h, or with
50 gM dicoumarol for 15 min and then with various concentrations of E09 for
1 h. Surviving cell fraction was determined by clonogenic assay (Begleiter et
al, 1989). The points represent the mean surviving cell fraction ± standard
error of 6-13 determinations. The lines are linear regression lines. Inset,
level of DT-diaphorase activity in control and cells treated with Oltipraz or
D3T. The bars represent the mean DT-diaphorase activity ± standard error of
four to ten determinations. The means were compared using a t-test
evaluating the significance of the difference of the DT-diaphorase activity in
the control and D3T analogue-treated cells
DT-diaphorase induction by D3T analogues
The structures of the D3T analogues used in this study are shown
in Figure 2. The analogues had substituents at either or both the 4-
and 5- positions of the disulphide ring structure. Some of the
analogues had unique features to their structure. Analogue 8 had a
S-oxide on the thione group; analogue 9 had a structure that corre-
sponded to a possible opened-ring metabolite of D3T, and
analogue 10 was the only compound that had a salt structure.
The ability of the D3T analogues to induce DT-diaphorase
activity was examined in eight cell lines from five tissue types: two
leukaemia cell lines, HL-60 and THP-1; two lung carcinoma cell
lines, NCI-H661 and NCI-H209; two colon carcinoma cell lines,
LS174T and HT29; one liver tumour cell line, HepG2; and one
breast cancer cell line, MCF-7. Cells were incubated with 100 JM of
each inducer for 48 h. The control and induced DT-diaphorase
enzyme activity levels forthesecell lines are summarized in Table 2.
The base levels of DT-diaphorase activity in HL-60 and THP-l
were 4.5 ± 0.5 and 26.1 ± 2.3 nmol MTT min-1 mg-' protein
respectively (Table 2). For the HL-60 cell line, 11 of the 13
analogues significantly induced DT-diaphorase activity, with the
induced levels ofDT-diaphorase activity ranging from 7.4 ± 0.8 to
38.4 ± 5.8 nmol MTT min-' mg-' protein. The best inducers ofDT-
diaphorase in the HL-60 cells were analogue 7, D3T, analogue 9
and Oltipraz. In the THP-l cell line, 12 ofthe 13 analogues signif-
icantly induced DT-diaphorase activity. DT-diaphorase activity in
induced cells ranged from 38.4 ± 6.3 to 124.2 ± 11.6 nmol MTT
min-' mg-' protein. The best inducers in the THP-1 cells were
analogue 7, D3T and analogue 8.
The NCI-H209 and NCI-H661 cell lines had base DT-
diaphorase activities of 8.3 ± 0.8 and 112.7 ± 12.4 nmol MTT
min-1 mg-' protein respectively. In the NCI-H209 cells, significant
induction occurred with only 4 ofthe 13 analogues, D3T, analogue
7, analogue 9, and analogue 4, and the induced activity ranged
from 13.6 ± 2.4 to 40.2 ± 3.1 nmol MTT min-' mg-' protein. In the
NCI-H661 cell line, 9 of the 13 analogues significantly
induced DT-diaphorase activity. The induced enzyme levels varied
from 168.0 ± 26.8 to 309.9 ± 58.9 nmol MTT min-' mg-' protein.
The best DT-diaphorase inducers were analogue 7, analogue 9
and D3T.
LS174T and HT29 had control DT-diaphorase activities of
314.6 ± 39.0 and 713.1 ± 47.4 nmol MTT min-' mg-' protein
respectively. In the LS174T cell line, 11 of the 13 analogues
increased DT-diaphorase activity levels significantly. Induced
levels varied from 482.7 ± 29.6 to 776.0 ± 97.5 nmol MTT min-'
mg-' protein. The best inducers were D3T, analogue 9, analogue 3
and analogue 4. Only three analogues significantly induced DT-
diaphorase activity in the HT29 cell line. The induced enzyme
levels ranged from 907.7 ± 78.5 to 1110.5 ± 87.4 nmol MTT min-
mg-' protein for analogue 5, D3T and analogue 8.
The base level of enzyme activity in the MCF-7 breast carci-
noma cells was 939.1 ± 88.3 nmol MTT min-1 mg-' protein, and
none of the D3T analogues increased DT-diaphorase activity
significantly. The control level of DT-diaphorase activity in the
hepatoma cell line HepG2 was also high, with a level of
1292.5 ± 162.0 nmol MTT min-1 mg-' protein, and no significant
induction of enzyme activity was observed with exposure to any
ofthe D3T analogues.
Induction of DT-diaphorase in human normal cells
The base level of DT-diaphorase activity in human bone marrow
cells was very low, 1.2 ± 0.4 nmol MIT min-1 mg-' protein;
however, incubation with D3T resulted in a small, but significant
increase in this activity to 12.7 ± 2.4 nmol MTT min-' mg-' protein
(P < 0.005) (Table 3). The base level of enzyme activity in 293
human kidney cells was also very low, 2.2 ± 0.3 nmol MTT min-]
mg-' protein, and D3T also increased DT-diaphorase activity in
these cells to 7.7 ± 0.1 nmol MTT min-1 mg-' protein (P < 0.001).
In contrast, WI-38 human lung cells had an intermediate base level
of DT-diaphorase activity, 76.5 ± 6.5 nmol MIT min-' mg-'
protein, and this was increased to 182.3 ± 12.2 nmol MTT min-'
mg-' protein (P < 0.002) by treatment with D3T.
Combination treatment with D3T analogues and
bioreductive anti-tumour agents
HL-60 cells were incubated with or without 50 gM Oltipraz or
50 gM D3T for 48 h and then with various concentrations ofE09
for 1 h. Cytotoxicity was determined by clonogenic assay (Figure
3). Treatment of HL-60 cells with 50 gM Oltipraz or 50 gM D3T
increased DT-diaphorase activity from 3.3 ± 0.4 to 5.8 ± 0.4
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Table 3 Induction of DT-diaphorase in human normal cells by D3T
Cells DT-diaphorase activity P
(nmol MTT min-' mg- protein)
Control D3T induced
Bone marrow 1.2 ± 0.4 12.7 ± 2.4 < 0.005
293 Kidney 2.2 ± 0.3 7.7 ± 0.1 < 0.001
WI-38 lung 76.5 ± 6.5 182.3 ± 12.2 < 0.002
Cells were incubated with or without 100gM D3T at 370C for 48 h. Cells were washed, pelleted,
suspended in 100-200gl of 0.25 M sucrose, sonicated and stored at -800C. DT-diaphorase activity
was measured as described in Materials and methods using menadione as the electron acceptor. The
data represent the mean ± standard error of three or four determinations. Statistical significance was
determined using a two-tailed t-test comparing the significance of the difference of the mean DT-
diaphorase activity in control and D3T-treated cells.
(P < 0.001) or 15.6 ± 1.5 (P < 0.001) nmol MTT min-' mg-'
protein respectively. Pretreatment with Oltipraz enhanced the
cytotoxicity of E09 in HL-60 cells with the Do decreasing from
6.1 ± 0.5 gM to 4.3 ± 0.3 gM (P < 0.02). Pretreatment with D3T
also increased the cytotoxicity ofE09 with theDodecreasing from
6.1 ±0.5 gM to 3.3 ±0.2gM (P <0.001), and this effect was signif-
icantly greater than the effect observed with Oltipraz (P < 0.05).
The addition of the DT-diaphorase inhibitor, dicoumarol, before
treatment with E09 reversed the increased cytotoxicity with D3T
(P < 0.005). In contrast, when 293 human normal kidney cells
were treated with 50gM D3T for 48 h, there was no significant
increase in DT-diaphorase activity compared with control cells,
and the cytotoxic activity ofE09 in these cells(Do = 31.7± 2.5 gM,
determined by MTT assay) did not change significantly when the
cells were pretreated with D3T (Figure 4).
H661 cells were incubated with or without 50gM analogue 8 or
50gM D3T for 48 h and then were treated with various concentra-
tions ofE09 for 1 h. Cytotoxicity was determined by MTT assay
(Figure 5). Treatment of H661 cells with 50gM analogue 8 or
50gM D3T increased DT-diaphorase activity from 168.4 ± 15.6 to
226.8 ± 17.9 (P < 0.05) or 266.7 ± 43.6 nmol MTT min-' mg-'
protein respectively. Pretreatment with analogue 8 or D3T
enhanced the cytotoxicity of E09 in H661 cells with the Do
decreasing from 0.7 ± 0.1 gM to 0.5 ± 0.1 0.1 JM (P < 0.05) or
0.5 ± 0.1 JIM (P < 0.05), respectively, but the effect of D3T was
not significantly different from that ofanalogue 8.
T47D human breast cancer cells were incubated with or without
75 JM D3T for 48 h and then were treated with various concentra-
tions ofMMC for 1 h. Cytotoxicity was determined by MTT assay
(Figure 6). Incubation ofthe cells with D3T increased the level of
DT-diaphorase activity from 25.8 ± 1.0 to 96.9 ± 5.6 nmol MTT
min-' mg-' protein (P < 0.001) and also significantly enhanced the
cytotoxicity of MMC by threefold. The Do decreased from
3.8 ± 0.1 JM forMMC alone to 1.2 ± 0.1 JM with D3T (P < 0.001).
DISCUSSION
DT-diaphorase is a highly inducible enzyme that can be an impor-
tant activating enzyme for bioreductive anti-tumour agents (Riley
and Workman, 1992; Ross et al, 1993). The enzyme has also been
shown to play an important role in detoxifying chemically reactive
metabolities in cells, thus protecting the cell from their toxic and
mutagenic effects (Beyer et al, 1988; Riley and Workman, 1992).
Recent studies have investigated the use of inducers of DT-
diaphorase in cancer prevention (Kelloffet al, 1990; Kensler et al,
1992; O'Dwyer et al, 1996). However, there have been few inves-
tigations of the potential use of inducers of DT-diaphorase to
enhance the anti-tumour activity of anti-tumour agents that are
activated by this enzyme. Shao et al (1995) found that the fish oil
menhaden oil increased DT-diaphorase activity in an MX-1,
human mammary carcinoma, tumour grown in athymic mice and
also increased the response ofthe tumour xenograft to MMC. We
have shown that D3T, an inducer of DT-diaphorase, can increase
the level of DT-diaphorase activity in murine lymphoma cells
without altering the level of enzyme activity in normal murine
marrow cells, resulting in an increase in the anti-tumour activities
ofMMC and E09 (Begleiter et al, 1996). In this study, we investi-
gated the ability of D3T analogues to induce DT-diaphorase in
different human tumour types and examined the ability of these
analogues to enhance the cytotoxic activity of the bioreductive
agents E09 and MMC in human tumours.
The results ofthis study demonstrated that D3T can increase the
level of DT-diaphorase activity in most human tumour cell types.
Overall, 28 of38 tumour cell lines showed significant increases in
enzyme activity after treatment with 100 JM D3T thatranged from
1.2- to 8.0-fold, or from 2.5 to 590 nmol MTT min-m mg-1 protein
in absolute terms (Table 1). Leukaemia, lung, colon, stomach,
breast, ovary, prostate and melanoma tumour cells lines were all
inducible. In contrast, three head and neck tumours and one liver
tumour were not induced by D3T. In addition, some tumour types
appeared to be more readily induced. For example, all the
leukaemia cell lines were induced, as were all the gastric tumour,
ovarian tumour and malignant melanoma cell lines. However, the
differences in inducibility of DT-diaphorase activity in the
different cell types may simply reflect the particular cell lines of
the tumour types examined in this study.
The mechanisms responsible for the differences in DT-
diaphorase induction in different cell lines are unknown.
Regulation ofexpression ofDT-diaphorase activity is complex and
may include regulation of transcription (Jaiswal, 1991; Belinsky
and Jaiswal, 1993; Yao and O'Dwyer, 1995; Wang and
Williamson, 1996), altemative splicing of DT-diaphorase mRNA
(Gasdaska et al, 1995; Hu et al, 1996; Yao et al, 1996) and the
presence of a polymorphism due to a mutation at position 609 of
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Figure 4 Effect of D3T on cytotoxic activity of E09 and on the DT-
diaphorase activity in 293, human normal kidney cells. Cells were incubated
at 370C with or without 50 gM D3T for 48 h. Cells were then treated with
various concentrations of E09 for 1 h. Surviving cell fraction was determined
by MUT assay (Johnston et al, 1994). The points represent the mean
surviving cell fraction ± standard error of five determinations. The lines are
linear regression lines. Inset, level of DT-diaphorase activity in control and
cells treated with D3T. The bars represent the mean DT-diaphorase
activity ± standard error of four determinations. The means were compared
using a t-test evaluating the significance of the difference of the
DT-diaphorase activity in the control and D3T-treated cells
the NQO1cDNA (Traver et al, 1992; Kuehl et al, 1995) that results
in a protein with very low enzyme activity (Traver et al, 1997).
Whether any ofthese mechanisms are responsible for the different
effects of the D3T analogues on DT-diaphorase activity in the
different human cell lines studied remains to be determined.
There was no obvious relationship between the base level of
DT-diaphorase activity in the tumour cells and the ability of D3T
to increase enzyme activity. Although four of the ten tumour cell
lines that were not induced by D3T had high base levels of DT-
diaphorase activity, all the melanoma tumours, and other cell lines,
that had high base levels of enzyme activity were induced. While
the increase in enzyme activity relative to the base level was low in
these cells, the absolute increase in enzyme activity was very high.
In addition, the oestrogen or androgen receptor status of the cells
did not appear to affect the induction ofDT-diaphorase. Ofthe six
breast cancer cell lines that were induced by D3T, three were
oestrogen receptor positive and three were oestrogen receptor
negative. Similarly, one of the two prostate cell lines that were
induced by D3T was androgen receptor positive while the other
was androgen receptor negative.
DT-diaphorase induction by D3T and 12 analogues was exam-
ined in five different tumour tissue types to identify any tissue-
specific DT-diaphorase induction profiles. Overall, the D3T
analogues did not appear to show any obvious tissue specificity for
Figure 5 Effect of analogue 8 or D3T on cytotoxic activity of E09 and DT-
diaphorase activity in H661, human large-cell lung tumour cells. Cells were
incubated at 370C with or without 50 gM analogue 8 or 50 gM D3T for 48 h.
Cells were then treated with various concentrations of E09 for 1 h. Surviving
cell fraction was determined by MTT assay (Johnston et al, 1994). The points
represent the mean surviving cell fraction ± standard error of seven to nine
determinations. The lines are linear regression lines. Inset, level of DT-
diaphorase activity in control and cells treated with analogue 8 or D3T. The
bars represent the mean DT-diaphorase activity ± standard error of four
determinations. The means were compared using a t-test evaluating the
significance of the difference of the DT-diaphorase activity in the control and
D3T analogue-treated cells
enzyme induction. However, some of the D3T analogues were
better inducers ofDT-diaphorase than others in the human tumour
cell lines examined, and this may indicate some structure-activity
relationships. The parent compound, D3T, was the most consistent
inducer, producing significant increases in enzyme activity in six
ofthe eight cell lines. Analogues 4, 5, 7, 8 and 9 were also consis-
tent inducers of DT-diaphorase activity, producing significant
increases in enzyme activity in five cell lines. Of these, D3T and
analogues 7, 8, and 9 generally produced the largest increases in
DT-diaphorase activity. In contrast, analogue 10 was the poorest
inducer in the cell lines studied. These results suggest that the
parent D3T is the best inducer of DT-diaphorase activity of the
analogues studied. However, the carbamoyl group in analogue 7,
the S-oxide in analogue 8 and the ring-opened structure in
analogue 9, in some instances, may produce greater increases in
DT-diaphorase activity than D3T. These studies do not indicate
any apparent difference in induction capacity between analogues
with substituents at position 4 or 5 of the D3T ring, but the salt
structure in analogue 10 may reduce induction capacity, possibly
as a result ofdecreased cellular uptake.
Talalay (1989) reviewed the structural requirements for induc-
tion of DT-diaphorase by monofunctional inducers and postulated
that the inducers are all Michael reaction acceptors, characterized
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Figure 6 Effect of D3T on cytotoxic activity of MMC and DT-diaphorase
activity in T47D, human breast cancer cells. Cells were incubated at 370C
with or without 75 gM D3T for 48 h. Cells were then treated with various
concentrations of MMC for 1 h. Surviving cell fraction was determined by
MUT assay (Johnston et al, 1994). The points represent the mean surviving
cell fraction + standard error of three to seven determinations. The lines are
linear regression lines. Inset, level of DT-diaphorase activity in control and
cells treated with D3T. The bars represent the mean DT-diaphorase
activity ± standard error of 6-11 determinations. The means were compared
using a t-test evaluating the significance of the difference of the
DT-diaphorase activity in the control and D3T analogue-treated cells
by olefinic or acetylenic linkages that are rendered electrophilic by
conjugation with electron-withdrawing groups. Prestera et al
(1993) also surveyed a list of DT-diaphorase inducers, including
D3T, and the only apparent universal property was their capacity
for reaction with sulphydryls by either oxidoreduction or alkyla-
tion. Structural modifications of D3T may, therefore, alter the
electrophilic character of the analogues or their ability to react
with sulphydryls.
Egner et al (1994) compared the induction of DT-diaphorase in
Hepa lclc7, mouse hepatoma cells, by 25 D3T analogues. This
group of analogues included D3T, Oltipraz, analogues 1-6, and
analogue 8, which we also examined in our study. Consistent with
our findings, D3T was one of the more potent DT-diaphorase
inducers in the Hepa IcIc7 cells. In addition, the 5-ethyl analogue
(analogue 4) and the S-oxide analogue (analogue 8) were rela-
tively potent inducers in both studies. In contrast, the 4-ethyl
analogue (analogue 3), the 4-phenyl analogue (analogue 6) and the
5-t-butyl analogue (analogue 5) were good inducers in Hepa c c7
cells but poor inducers in the human tumour cell lines.
Furthermore, the ring-opened analogue (analogue 9) was a good
inducer of DT-diaphorase in human tumours, but a ring-opened
analogue of Oltipraz was inactive in the mouse hepatoma cells.
Comparison of the results of these two studies indicate both simi-
larities and differences in induction of DT-diaphorase by D3T
analogues in human and mouse tumour cells. Whether these relate
to species differences or differences in tumour type is unknown.
The base levels of DT-diaphorase activity were very low in the
normal marrow and kidney cells that we examined. While D3T
produced significant increases in enzyme activity in these cells,
the actual increases were only 11.5 and 5.5 nmol MTT min-' mg-'
protein, respectively, less than halfthe increase observed in HL-60
leukaemia cells. In contrast, D3T increased the level of DT-
diaphorase activity in normal human lung cells by 2.4-fold.
Combination treatment with Oltipraz or D3T and E09 increased
the anti-tumour activity of E09 in HL-60, human promyelocytic
leukaemia cells (Figure 3). Oltipraz and D3T increased the level of
DT-diaphorase activity in these cells by 1.7- and 4.7-fold, respec-
tively (P < 0.001), and also increased the cytotoxic activity ofE09
by 1.4- and 1.8-fold, respectively, in these cells (P < 0.02). The
increased cytotoxic activity was due to the elevated DT-diaphorase
activity, as dicoumarol, an inhibitor of the enzyme, reversed the
effect of D3T on E09 cytotoxic activity (P < 0.005). In addition,
D3T did not increase the activities of NADPH:cytochrome P450
reductase, NADH:cytochrome b5 reductase or xanthine dehydro-
genase, other enzymes that can activate bioreductive agents (Pan
et al, 1984; Gustafson and Pritsos, 1992; Hodnick and Sartorelli,
1993), in these cells.
Pretreatment of H661, human non-small-cell lung cancer cells
with analogue 8 or D3T significantly increased the cell kill
observed with E09 by 1.5- and 1.6-fold respectively (P < 0.05)
(Figure 5). The enhancement of E09 cytotoxicity by the D3T
analogues parallelled their effect on induction of DT-diaphorase.
Thus, other D3T analogues that produce greater induction of DT-
diaphorase activity may further enhance the cytotoxic activity of
bioreductive agents. Similarly, combination treatment with D3T
and MMC increased the anti-tumour activity of MMC in T47D,
human breast carcinoma cells (Figure 6). D3T increased the level
ofDT-diaphorase activity in these cells by 3.8-fold (P<0.001) and
also increased the cytotoxic activity ofMMC by threefold in these
cells (P < 0.001).
The major toxicities observed with MMC and E09 are bone
marrow and kidney toxicity respectively (Hortobagyi, 1993;
Schellens et al, 1994). Treatment with 100gM D3T produced
small, but significant, increases in the levels of DT-diaphorase
activity in normal human marrow and kidney cells. Because the
increases in DT-diaphorase activities were very small in these
cells, it is unlikely that the toxicity to these cells would be signifi-
cantly increased. Indeed, 50gM D3T did not effect the toxicity of
E09 in the human normal kidney cells, but this concentration of
D3T did not significantly increase DT-diaphorase activity in the
kidney cells. Furthermore, we have shown previously that D3T did
not increase the toxicity of MMC to mouse marrow cells
(Begleiter et al, 1996). In contrast, the increase in enzyme activity
in the normal human lung cells was considerably larger. This
effect might increase MMC toxicity to normal lung tissues in a
clinical setting. However, MMC has been shown to produce
pulmonary fibrosis in approximately 5% of patients (Klein and
Wilds, 1983) by a mechanism that probably involves redox
cycling and the formation of reactive oxygen species. Thus, it is
possible that the increase in DT-diaphorase activity in normal lung
cells with D3T treatment may serve to decrease this lung toxicity,
as two-electron reduction of MMC to its hydroquinone by DT-
diaphorase would decrease reactive oxygen species formation.
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The overall effect ofDT-diaphorase induction on MMC toxicity in
the lung will need to be assessed in an in vivo study.
These studies do not provide any conclusive evidence about the
level of increase in DT-diaphorase activity that is required to
increase the cytotoxic activity of the bioreductive anti-tumour
agents. It is not known whether there is a threshold of induction
that must be exceeded before the cytotoxic activity of the bio-
reductive agents is increased. For example, an increase in DT-
diaphorase activity of2.5 nmol MTT min-' mg-' protein in HL-60,
human leukaemia cells, produced by 50gM D3T, increased cell
kill by E09 by 1.4-fold, while an increase in enzyme activity of
1.1 nmol MTT min-' mg-' protein in 293, human normal kidney
cells, also produced by 50gM D3T, had no effect on E09 activity
in these cells. Ifthere is a threshold level ofDT-diaphorase induc-
tion required for an effect on the activity ofbioreductive agents, it
is still unclear whether this level will be the same for all cells or,
as is more likely, the level will be different in different cells.
Furthermore, it is not known whether the absolute level ofincrease
in DT-diaphorase activity or the level of increase relative to the
base level ofenzyme activity is most important fordetermining the
effect on the cytotoxic activity of the anti-tumour agents. Despite
these ambiguities, this study demonstrates that non-toxic concen-
trations of D3T analogues can produce large increases in DT-
diaphorase activity in a wide variety of human tumour cells and
can enhance the anti-tumour activity ofE09 and MMC with only
small effects on normal kidney and marrow cells, which represent
the most important sites of clinical toxicity to these bioreductive
agents.
The GSTs are a family of phase II detoxifying enzymes that
have been shown to be coordinately induced with DT-diaphorase
in some tissues (Talalay, 1989). These enzymes may also protect
cells from the toxic and mutagenic effects of foreign chemicals
(Prestera et al, 1993). In addition, GSTs have been shown to play
an important role in resistance to a variety of anti-tumour agents,
including MMC, by aiding in the removal of the drugs from cells
(Waxman, 1990; Xu etal, 1994). Thus, ifD3T were to increase the
levels ofboth DT-diaphorase and GSTactivity in tumourcells, this
might not result in a net increase in anti-tumour activity. This did
not occur in our studies as we did observe an increase in anti-
tumour activity with both E09 and MMC in three tumour cell
lines. Furthermore, we did not see any increase in GST activity in
HL-60 cells treated with D3T, as has been observed previously (Li
et al, 1994). Therefore, it appears that it is possible to increase DT-
diaphorase activity in tumour cells without increasing GST.
Additional studies are required to determine whether this effect is
observed in other tumour cells, in normal tissues or with other
inducers.
In summary, we have shown that D3T analogues significantly
increased the level of DT-diaphorase activity in 28 of 38 human
tumour cells representing a wide variety of tumour types. DT-
diaphorase activity was also increased in normal human bone
marrow and kidney cells, but the increases were small in these
cases. D3T produced a significant increase in enzyme activity in
normal human lung cells. Modifications to the basic D3T struc-
ture, such as the 5-carbamoyl substituent, the S-oxide function, or
opening ofthe dithiolethione ring may increase the enzyme induc-
tive capacity. D3T analogues thatcombine these structural features
may prove to be better inducers of DT-diaphorase. Additional
studies are required to identify D3T analogues that produce the
optimum selective increase in DT-diaphorase activity in tumour
cells compared with normal cells.
Combination treatment of human tumour cells with D3T
analogues and the bioreductive anti-tumour agents, MMC orE09,
produced significant increases in cytotoxic activity in human
tumour cells, and the level ofenhancement ofanti-tumour activity
paralleled the level of DT-diaphorase induction. In contrast, D3T
did not effect the toxicity of E09 in normal kidney cells. Thus, it
may be possible to use inducers of DT-diaphorase to enhance the
effectiveness ofbioreductive anti-tumour agents that are activated
by this enzyme. This approach appears to be applicable to different
agents and in different tumour cells. The development of D3T
analogues that are more potent and selective inducers of DT-
diaphorase would increase the potential use of this therapeutic
approach. Additional studies with other inducers, anti-tumour
agents and cells are required to identify the optimum uses for this
new treatment strategy.
ACKNOWLEDGEMENTS
We are grateful to the Medical Research Council of Canada,
Manitoba Cancer Treatment and Research Foundation, Manitoba
Health Research Council, the University of Manitoba, and the
National Cancer Institute, USA (CA39416), for financial support.
GPD and XW are recipients ofGeorge H Sellers Studentships.
REFERENCES
Atallah AS, Landolph JR, Emster L and Hochstein P (1988) DT-diaphorase activity
and the cytotoxicity ofquinones in C3H/lOT1/2 mouse embryo cells. Biochem
Pharmacol 37: 2451-2459
Barham HM, Inglis R, Chinje EC and Stratford IA (1996) Development and
validation of a spectrophotometric assay for measuring the activity ofNADH:
cytochrome b5 reductase in human tumor cells. BrJ Cancer74: 1188-1193
Beall HD, Liu YF, Siegel D, Bolton EM, Gibson NW and Ross D (1996) Role of
NAD(P)H:quinone oxidoreductase (DT-diaphorase) in cytotoxicity and
induction ofDNA damage by streptonigrin. Biochem Pharnacol 51: 645-652
Begleiter A and Leith MK (1990) Activity ofquinone alkylating agents in quinone-
resistant cells. CancerRes 50: 2872-2876
Begleiter A and Leith MK (1995) Induction ofDT-diaphorase by doxorubicin and
combination therapy with mitomycin C in vitro. Biochem Pharmacol 50:
1281-1286
Begleiter A, Robotham E, Lacey G and Leith MK (1989) Increased sensitivity of
quinone resistant cells to mitomycin C. CancerLett 45: 173-176
BegleiterA, Robotham E and Leith MK (1992) Role ofNAD(P)H:(quinone
acceptor)oxidoreductase (DT-diaphorase) in activation ofmitomycin C under
hypoxia. Mol Pharmacol 41: 677-682
Begleiter A, Leith MK and Curphey TJ (1996) Induction ofDT-diaphorase by 1,2-
dithiole-3-thione and increase ofantitumour activity ofbioreductive agents.
BrJ Cancer74 (suppl. 27): S9-S14
Belcourt MF, Hodnick WF, Rockwell S and Sartorelli AC (1996) Differential
toxicity ofmitomycin C and porfiromycin to aerobic and hypoxic Chinese
hamster ovary cells overexpressing human NADPH:cytochrome c (P-450)
reductase. ProcNatlAcad Sci USA 93: 456-460
Belinsky M and Jaiswal AK (1993) NAD(P)H:quinone oxidoreductasel (DT-
diaphorase) expression in normal and tumor tissues. CancerMetastasis Rev 12:
103-117
Benson AM, Hunkeler MJ and Talalay P (1980) Increase ofNAD(P)H:quinone
reductase by dietary antioxidants: possible role in protection against
carcinogenesis and toxicity. Proc NatlAcad Sci USA 77: 5216-5220
Beyer RE, Segura Aguilar JE and Emster L (1988) The anticancer enzyme DT-
diaphorase is induced selectively in liver during ascites hepatoma growth.
Anticancer Res 8: 233-238
Bueding E, Dolan P and Leroy JP (1982) The antischistosomal activity ofoltipraz.
Res Commun Chem Pathol Pharmacol 37: 293-303
Egner PA, Kensler TW, Prestera T, Talalay P, Libby AH, Joyner HH and Curphey TJ
(1994) Regulation ofphase 2 enzyme induction by oltipraz and other
dithiolethiones. Carcinogenesis 15: 177-181
Fitzsimmons SA, Workman P, Grever M, Paull K, Camalier R and Lewis AD (1996)
Reductase enzyme expression across the National Cancer Institute tumor cell
C Cancer Research Campaign 1998 British Journal ofCancer(1998) 77(8), 1241-12521252 GP Doherty etal
line panel: correlation with sensitivity to mitomycin C and E09. JNatl Cancer
Inst 88: 259-269
Gasdaska PY, Fisher H and Powis G (1995) An alternatively spliced form ofNQO1
(DT-diaphorase) messenger RNA lacking the putative quinone substrate
binding site is present in human normal and tumor tissues. Cancer Res 55:
2542-2547
Gustafson DL and Pritsos CA (1992) Bioactivation ofmitomycin C by xanthine
dehydrogenase from EMT6 mouse mammary carcinoma tumors. JNatl Cancer
Inst 84: 1180-1185
Gustafson DL, Swanson JD and Pritsos CA (1991) Role ofxanthine oxidase in the
potentiation ofdoxorubicin-induced cardiotoxicity by mitomycin C. Cancer
Commun 3: 1-6
Habig WH, Pabst MJ and Jakoby WB (1974) Glutathione S-transferase, The first
enzymatic step in mercaptouric acid formation. JBiol Chem 249: 7130-7139
Hodnick WF and Sartorelli AC (1993) Reductive activation ofmitomycin C by
NADH:cytochrome bS reductase. Cancer Res 53: 4907-4912
Hortobagyi GN (1993) Mitomycin: its evolving role in the treatment ofbreast
cancer. Oncol 50 (suppl. 1): 1-8
Hu LT, Stamberg J and Pan SS (1996) The NAD(P)H:quinone oxidoreductase locus
in human colon carcinoma HCT 116 cells resistant to mitomycin C. Cancer
Res 56: 5253-5259
Jaiswal AK (1991) Human NAD(P)H:quinone oxidoreductase (NQO-1) gene
structure and induction by dioxin. Biochemistry 30: 10647-10653
Jaiswal AK, Burnett P, Adesnick M and McBride OW (1990) Nucleotide and
deduced amino acid sequence ofa human cDNA (NQO2) corresponding to a
second member ofthe NAD(P)H:quinone oxidoreductase gene family.
Extensive polymorphism at the NQO2 gene locus on chromosome 6.
Biochemistry 29: 1899-1906
Johnston JB, Verburg L, Shore T, Williams M, Israels LG and Begleiter A (1994)
Combination therapy with nucleoside analogs and alkylating agents. Leukemia
8(suppl.): S140-S143
Kelloff GJ, Malone WF, Boone CW, Sigman CC and Fay JR (1990) Progress in
applied chemoprevention research. Semin Oncol 17: 438-455
Kensler TW and Helzlsouer KJ (1995) Oltipraz: clinical opportunities for cancer
chemoprevention. J Cell Biochem suppl. 22: 101-107
Kensler T, Styczynski P, Groopman J, Helzlsouer K, Curphey T, Maxuitenko Y and
Roebuck BD (1992) Mechanisms ofchemoprevention by oltipraz. J Cell
Biochem suppl. 161: 167-172
Klein DS and Wilds PR (1983) Pulmonary toxicity ofantineoplastic agents:
anaesthetic and postoperative implications. CanAnaesth Soc J30: 399-405
Kuehl BL, Paterson JWE, Peacock JW, Paterson MC and Rauth AM (1995)
Presence ofa heterozygous substitution and its relationship to DT-diaphorase
activity. BrJ Cancer 72: 555-561
Li Y, Lafuente A and Trush MA (1994) Characterization ofquinone reductase,
glutathione and glutathione S-transferase in human myeloid cell lines:
induction by 1,2-dithiole-3-thione and effects on hydroquinone-induced
cytotoxicity. Life Sci 54: 901-916
Malkinson AM, Siegel D, Forrest GL, Gazdar AF, Oie HK, Chan DC, Bunn PA,
Mabry M, Dykes DJ, Harrison SD and Ross D (1992) Elevated DT-diaphorase
activity and messenger RNA content in human non-small lung carcinoma:
relationship to the response oflung xenografts to mitomycin C. Cancer Res 52:
4752-4757
Maxuitenko YY, Curphey TJ, Kensler TW and Roebuck BD (1996) Protection
againt aflatoxin B,-induced hepatic toxicity as a short-term screen ofcancer
chemopreventive dithiolethiones. FundAppl Toxicol 32: 250-259
Mikami K, Naito M, Tomida A, Yamada M, Sirakusa T and Tsuruo T (1996) DT-
diaphorase as a critical determinant of sensitivity to mitomycin C in human
colon and gastric carcinoma cell lines. CancerRes 56: 2823-2826
Nishiyama M, Saeki S, Aogi K, Hirabayashi N and Toge T (1993) Relevance ofDT-
diaphorase activity to mitomycin C (MMC) efficacy on human cancer cells:
differences in in vitro and in vivo systems. IntJ Cancer 53: 1013-1016
O'Dwyer PJ, Szarka CE, Yao K-S., Halbherr TC, Pfeiffer GR, Green F, Gallo JM,
Brennan J, Frucht H, Goosenberg EB, Hamilton TC, Litwin S, Balshem AM,
Engstrom PF and Clapper ML (1996) Modulation ofgene expression in
subjects at risk for colorectal cancer by the chemopreventative dithiolethione
Oltipraz. J Clin Invest 98: 1210-1217
Pan SS, Andrews PA, Glover CJ and Bachur NR (1984) Reductive activation of
mitomycin C and mitomycin C metabolites catalyzed by NADPH-cytochrome
P-450 reductase and xanthine oxidase. JBiol Chem 259: 959-966
Patterson AV, Robertson N, Houlbrook S, Stephens MA, Adams GE, Harris AL,
Stratford IJ and Carmichael J (1994) The role ofDT-diaphorase in determining
the sensitivity ofhuman tumor cells to tirapazamine (SR 4233). IntJRadiat
Oncol Biol Phys 29: 369-372
Plumb JA, Gerritsen M, Milroy R, Thomson P and Workman P (1994) Relative
importance ofDT-diaphorase and hypoxia in the bioactivation ofE09 by
human lung tumor cell lines. IntJRadiat Oncol Biol Phys 29: 295-299
Powis G, Gasdaska PY, Gallegos A, Sherrill K and Goodman D (1995) Over-
expression ofDT-diaphorase in transfected NIH 3T3 cells does not lead to
increased anticancer quinone drug sensitivity: a questionable role for the
enzyme as a target for bioreductively activated anticancer drugs. Anticancer
Res 15: 1141-1145
Prestera T, Zhang Y, Spencer SR, Wilczak CA and Talalay P (1993) The electrophile
counterattack response: protection against neoplasia and toxicity. Adv Enzyme
Regul 33: 281-296
Prochaska HJ and Santamaria AB (1988) Direct measurement ofNAD(P)H:quinone
reductase from cells cultured in microtiter wells: a screening assay for
anticarcinogenic enzyme inducers. Anal Biochem 169: 328-336
Riley RJ and Workman P (1992) DT-diaphorase and cancer chemotherapy. Biochem
Pharmacol 43:1657-1669
Ross D, Siegel D, Beall H, Prakash AS, Mulcahy RT and Gibson NW (1993) DT-
diaphorase in activation and detoxification ofquinones. CancerMetastasis Rev
12: 83-101
Schellens JHM, Planting AST, Van Acker BAC, Loos WJ, De Boer-Dennert M, Van
der Burg MEL, Koier I, Krediet RT, Stoter G and Verweij J (1994) Phase I and
pharmacologic study ofthe novel indoloquinone bioreductive alkylating
cytotoxic drug E09. JNatl CancerInst86: 906-912
Schlager JJ and Powis G (1990) Cytosolic NAD(P)H:(quinone-
acceptor)oxidoreductase in human normal and tumour tissue: effects of
cigarette smoking and alcohol. IntJ Cancer45: 403-409
Shao Y, Pardini L and Pardini RS (1995) Dietary menhaden oil enhances mitomycin
C antitumor activity toward human mammary carcinoma MX-1. Lipids 30:
1035-1045
Siegel D, Gibson NW, Preusch PC and Ross D (1990) Metabolism ofdiaziquone by
NAD(P)H:(quinone acceptor) oxidoreductase (DT-diaphorase): role in
diaziquone-induced DNA damage and cytotoxicity in human colon carcinoma
cells. Cancer Res 50: 7293-7300
Smitskamp-Wilms EG, Giaccone G, Pinedo HM, Van der Laan BFAM and Peters GJ
(1995) DT-diaphorase activity in normal and neoplastic human tissues: an
indicator for sensitivity to bioreductive agents? BrJ Cancer 72: 917-921
Strobel HW and Dignam JD (1978) Purification and properties ofNADPH-
cytochrome P-450 reductase. Methods Enzymol 52: 89-96
Talalay P (1989) Mechanisms ofinduction ofenzymes that protect against chemical
carcinogenesis. Adv Enzyme Regul 28: 237-250
Traver RD, Horikoshi T, Danenberg KD, Stadlbauer TH, Danenberg PV, Ross D
and Gibson NW (1992) NAD(P)H:quinone oxidoreductase gene expression
in human colon carcinoma cells: characterization of a mutation which
modulates DT-diaphorase activity and mitomycin sensitivity. Cancer Res 52:
797-802
Traver RD, Siegel D, Beall HD, Phillips RM, Gibson NW, Franklin WA and Ross D
(1997) Characterization ofa polymorphism in NAD(P)H:quinone
oxidoreductase (DT-diaphorase). BrJ Cancer75: 69-75
Wang B and Williamson G (1996) Transcriptional regulation ofthe human
NAD(P)H:quinone oxidoreductase (NQO,) gene by monofunctional inducers.
Biochim Biophys Acta 1307: 104-110
Waxman DJ (1990) Glutathione S-transferases: role in alkylating agent resistance
and possible target for modulation chemotherapy - a review. Cancer Res 50:
6449-6454
Workman P and Stratford IJ (1993) The experimental development ofbioreductive
drugs and their role in cancer therapy. CancerMetastasis Rev 12: 73-82
Yao KS and O'Dwyer PJ (1995) Involvement ofNF-kappaB in the induction of
NAD(P)H:quinone oxidoreductase (DT-diaphorase) by hypoxia, oltipraz and
mitomycin. Biochem Pharmacol 49: 275-282
Yao KS, Godwin AK, Johnson C and O'Dwyer PJ (1996) Altemative splicing and
differential expression ofDT-diaphorase transcripts in human colon tumors and
in peripheral mononuclear cells in response to mitomycin C treatment. Cancer
Res 56: 1731-1736
Xu BH, Gupta V and Singh SV (1994) Characterization ofa human bladder cancer
cell line selected for resistance to mitomycin C. IntJCancer 58: 686-692
British Journal ofCancer (1998) 77(8), 1241-1252 @ CancerResearch Campaign 1998